<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="HODGKIN LYMPHOMA æ—å”éœ†  Epidemiology  Represents ~12% of lymphomas ~8â€“9K cases annually in US, resulting in ~1300 deaths Typically affects younger pts (20sâ€“30s) but can also affect older adults  Biology/Pathology  2 major types: Classical HL, NLPHL  Classical HL Reedâ€“Sternberg Cell:"><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle="><title>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.9422ebf6ba0889a950feb47330bafa38.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.8c890c0ab5916d5b1ce74859205052b4.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=æœå°‹ placeholder="è«‹è¼¸å…¥åƒæ˜¯ï¼šhypertension ä¹‹é¡çš„ä¾†çœ‹æ²’æœ‰æ²’ä»€éº¼æœ‰è¶£çš„ğŸ³"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>èœ¥èœ´èŠ±åœ’ğŸ¦ğŸŒ±ğŸª´ğŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>æœå°‹</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">æœå°‹åœ–ç¤º</title><desc id="desc">æ‰“é–‹æœå°‹åœ–æ¨™</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>æ˜äº®æ¨¡å¼</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>é»‘æš—æ¨¡å¼</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>æœ€å¾Œæ›´æ–°æ–¼
Aug 28, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/slides/HODGKIN%20LYMPHOMA.md rel=noopener>ğŸªš ç·¨è¼¯åŸå§‹æ–‡ä»¶</a></p><ul class=tags></ul><aside class=mainTOC><details><summary>ğŸ“’ç›®éŒ„</summary><nav id=TableOfContents><ol><li><ol><li></li></ol></li><li><a href=#epidemiology>Epidemiology</a></li><li><a href=#biologypathology>Biology/Pathology</a><ol><li><a href=#classical-hl>Classical HL</a></li><li><a href=#nlphl>NLPHL</a></li></ol></li><li><a href=#workup>Workup</a></li><li><a href=#staging>Staging</a></li><li><a href=#modifier>MODIFIER</a></li><li><a href=#risk-factors>Risk Factors</a><ol><li><a href=#early-stage>Early stage:</a></li><li><a href=#advanced-stage>Advanced stage:</a></li></ol></li><li><a href=#management>Management</a><ol><li><a href=#early-stage-disease>Early Stage Disease</a></li><li><a href=#advanced-stage-disease>Advanced Stage Disease</a></li><li><a href=#relapsed-classical-hodgkin-lymphoma>Relapsed Classical Hodgkin Lymphoma</a></li></ol></li><li><a href=#rfs-for-adverse-outcome-post-relapse-blood-200197616>RFs for adverse outcome post relapse (Blood 2001;97:616):</a></li><li><a href=#toxicity>Toxicity</a></li></ol></nav></details></aside><a href=#hodgkin-lymphoma><h1 id=hodgkin-lymphoma><span class=hanchor arialabel=Anchor># </span>HODGKIN LYMPHOMA</h1></a><a href=#æ—å”éœ†><h4 id=æ—å”éœ†><span class=hanchor arialabel=Anchor># </span>æ—å”éœ†</h4></a><hr><a href=#epidemiology><h2 id=epidemiology><span class=hanchor arialabel=Anchor># </span>Epidemiology</h2></a><ul><li>Represents ~12% of lymphomas</li><li>~8â€“9K cases annually in US, resulting in ~1300 deaths</li><li>Typically affects younger pts (20sâ€“30s) but can also affect older adults</li></ul><a href=#biologypathology><h2 id=biologypathology><span class=hanchor arialabel=Anchor># </span>Biology/Pathology</h2></a><ul><li>2 major types: Classical HL, NLPHL</li></ul><a href=#classical-hl><h3 id=classical-hl><span class=hanchor arialabel=Anchor># </span>Classical HL</h3></a><p>Reedâ€“Sternberg Cell:</p><ul><li>large, multinucleated cell w/ classic â€œowlâ€™s eyesâ€ appearance</li><li>stains (+) for CD15 & CD30</li></ul><hr><a href=#subtypes-of-classical-hl-include><h4 id=subtypes-of-classical-hl-include><span class=hanchor arialabel=Anchor># </span>Subtypes of Classical HL include:</h4></a><ul><li>nodular sclerosis (most common)</li><li>lymphocyte rich,</li><li>mixed cellularity, & lymphocyte depleted.</li></ul><p>Tx does not differ among these subtypes</p><a href=#the-most-common-genetic-alterations-in-chl><h4 id=the-most-common-genetic-alterations-in-chl><span class=hanchor arialabel=Anchor># </span>The most common genetic alterations in cHL</h4></a><ul><li>amplification of 9p24.1 containing the PD-L1, PD-L2, & JAK2 genes as well as Mts of the beta-2 microglobulin gene resulting in immune evasion</li></ul><blockquote><p>(Blood 2010; 116: 3268, Blood 2015; 125:1061)</p></blockquote><hr><a href=#nlphl><h3 id=nlphl><span class=hanchor arialabel=Anchor># </span>NLPHL</h3></a><p>a more indolent disease characterized by the Lymphocytic & Histiocytic cell, a Reedâ€“Sternberg variant that stains negative for CD15 & CD30, but (+) for CD20</p><a href=#workup><h2 id=workup><span class=hanchor arialabel=Anchor># </span>Workup</h2></a><ul><li>Excisional bx preferred for initial dx;</li><li>core-needle bx may be adequate,</li><li>FNA inadequate</li><li>Cross-sectional imaging w/ PET/CT
BM bx no longer required as it does not upstage pts who are early stage by PET</li><li>Echo if anthracycline to be used, PFTs if bleomycin to be used</li></ul><a href=#staging><h2 id=staging><span class=hanchor arialabel=Anchor># </span>Staging</h2></a><blockquote><p>Cotswolds modification of the Ann Arbor Staging System (JCO1989;7:1630)</p></blockquote><table><thead><tr><th>stage</th><th>Description</th></tr></thead><tbody><tr><td>I</td><td>Single LN or nodal group</td></tr><tr><td>II</td><td>2 or more nodal groups on the same side of the diaphragm</td></tr><tr><td>III</td><td>LN groups on both sides of the diaphragm</td></tr><tr><td>IV</td><td>Disseminated extranodal disease</td></tr></tbody></table><a href=#modifier><h2 id=modifier><span class=hanchor arialabel=Anchor># </span>MODIFIER</h2></a><table><thead><tr><th>Modifier</th><th>Description</th></tr></thead><tbody><tr><td>B</td><td>â€œBâ€ sx: Unexplained fever, wt. loss (â‰¥10% of wt.) or night sweats (drenching)</td></tr><tr><td>A</td><td>Absence of â€œBâ€ sx</td></tr><tr><td>X</td><td>Bulky disease (â‰¥10 cm or 1/3 of intrathoracic diameter)</td></tr><tr><td>E</td><td>Extranodal extension: Limited involvement of an extralymphatic organ contiguous w/ a nodal site</td></tr><tr><td>S</td><td>Spleen involvement</td></tr></tbody></table><a href=#risk-factors><h2 id=risk-factors><span class=hanchor arialabel=Anchor># </span>Risk Factors</h2></a><a href=#early-stage><h3 id=early-stage><span class=hanchor arialabel=Anchor># </span>Early stage:</h3></a><p>unfavorable criteria include Age â‰¥50, ESR >50 or >30 if +B sx, bulky disease, 3+ nodal regions involved</p><a href=#advanced-stage><h3 id=advanced-stage><span class=hanchor arialabel=Anchor># </span>Advanced stage:</h3></a><p>IPS includes 7 RFs for adverse outcome (NEJM 1998; 339:1506):
Serum albumin &lt;4 g/dLHb &lt;10.5 g/dLMale sex
WBC â‰¥15KAge â‰¥45Stage IV
Lymphocyte count &lt;600/mm3 or &lt;8% of WBC</p><a href=#management><h2 id=management><span class=hanchor arialabel=Anchor># </span>Management</h2></a><a href=#early-stage-disease><h3 id=early-stage-disease><span class=hanchor arialabel=Anchor># </span>Early Stage Disease</h3></a><a href=#i-iia-favorable-nonbulky><h4 id=i-iia-favorable-nonbulky><span class=hanchor arialabel=Anchor># </span>I-IIA, favorable, nonbulky</h4></a><table><thead><tr><th>Treatment</th><th>Notes</th></tr></thead><tbody><tr><td>ABVD Ã—2 + ISRT 20 Gy</td><td>HD10: 2c NI 4c, 20 Gy NI 30 Gy</td></tr><tr><td>ABVD Ã—3 â†’ obs if PET-negative</td><td>RAPID (NEJM 2015): ABVD Ã—1c + ISRT 30 Gy if PET+</td></tr></tbody></table><ul><li>Adriamycin (doxorubicin), Bleomycin, Vinblastine, and Dacarbazine.</li><li>NI: No Involvement</li></ul><hr><a href=#i-ii-unfavorable-nonbulky><h4 id=i-ii-unfavorable-nonbulky><span class=hanchor arialabel=Anchor># </span>I-II, unfavorable, nonbulky</h4></a><table><thead><tr><th>Treatment</th><th>Notes</th></tr></thead><tbody><tr><td>ABVD Ã—4 + ISRT 30 Gy</td><td>20 Gy insufficient (HD11, JCO 2010)</td></tr><tr><td>ABVD Ã—3 â†’ obs if PET-negative</td><td>RAPID (as above)</td></tr><tr><td>ABVD Ã—4 â†’ obs</td><td>If PET-negative after 2c (CALGB/Alliance 50604)</td></tr></tbody></table><a href=#iii-bulky><h4 id=iii-bulky><span class=hanchor arialabel=Anchor># </span>Iâ€“II, bulky</h4></a><table><thead><tr><th></th><th></th></tr></thead><tbody><tr><td>ABVD Ã—4 + ISRT 30 Gy</td><td>7 cm or larger likely requires ISRT (Kumar Hematologica 2016)</td></tr></tbody></table><hr><a href=#advanced-stage-disease><h3 id=advanced-stage-disease><span class=hanchor arialabel=Anchor># </span>Advanced Stage Disease</h3></a><a href=#iibx-iii-iv><h4 id=iibx-iii-iv><span class=hanchor arialabel=Anchor># </span>IIBX, III, IV</h4></a><a href=#abvd-6c-w-pet-after-2c><h5 id=abvd-6c-w-pet-after-2c><span class=hanchor arialabel=Anchor># </span>ABVD Ã—6c w/ PET after 2c</h5></a><ul><li>AVD for cycles 3-6 NI ABVD if PET-2 negative</li><li>Escalation to escBEACOPP if PET-2 positive may increase cure rate (RATHL, NEJM 2016)</li></ul><a href=#escbeacopp-6c-w-pet-after-2c><h4 id=escbeacopp-6c-w-pet-after-2c><span class=hanchor arialabel=Anchor># </span>escBEACOPP Ã—6c w/ PET after 2c</h4></a><ul><li>Reserve for pts w/ high-risk (IPS 4+) disease</li><li>Consider de-escalating to ABVD if PET-negative after 2c (AHL2011 LYSA, ASH 2015)</li></ul><hr><p>Risk of infection low even in neutropenic pts not receiving G-CSF: tx delays should be avoided. Neutropenia does not necessitate a dose delay or reduction
All pts would have end-of-treatment PET; if positive bx. If negative bx consider consolidative RT if not already given; if positive proceed to salvage therapy</p><hr><a href=#relapsed-classical-hodgkin-lymphoma><h3 id=relapsed-classical-hodgkin-lymphoma><span class=hanchor arialabel=Anchor># </span>Relapsed Classical Hodgkin Lymphoma</h3></a><ul><li>Most pts should receive salvage chemotherapy such as ICE, DHAP, or GVD (JCO 1993;11:1062) followed by consolidative autologous stem cell transplant if responsive</li><li>The most important pre-SCT predictor of outcomes is achievement of a PET-negative CR regardless of whether 1 or 2 salvage regimens is required (Blood 2012;119:1665)
Single agent Brentuximab can achieve CRs in 25â€“30% of pts & avoid multiagent chemotherapy in a subset of pts (Lancet Oncol 2015;16:284)</li></ul><hr><ul><li>Consolidative RT to sites involved w/ disease at relapse is typically administered to pts w/ early stage disease at relapse who were not previously irradiated</li></ul><a href=#rfs-for-adverse-outcome-post-relapse-blood-200197616><h2 id=rfs-for-adverse-outcome-post-relapse-blood-200197616><span class=hanchor arialabel=Anchor># </span>RFs for adverse outcome post relapse (Blood 2001;97:616):</h2></a><ul><li>Remission duration &lt;12 mos</li><li>B-sx</li><li>Extranodal disease</li><li>In these pts, maintenance Brentuximab q3w Ã— 12 mos improves PFS (AETHERA, Lancet Oncol 2015)</li></ul><hr><p>In pts relapsing after autologous SCT, 2 strategies are particularly effective:
Brentuximab vedotin has 75% RR in post-ASCT setting & achieves long-term remissions in about 20% of pts achieving a CR (Chen, Blood 2016)
PD-1 blockade w/ nivolumab or pembrolizumab has a 65â€“70% RR & achieves long-term (>1 y) remissions in at least 40% (Lancet Oncol 2016:17:1283; JCO 2016;34:2698)
Role of allogeneic transplant is unclear, particularly for pts receiving PD-1 blockade given the increased risk of post-allo SCT GVHD in pts w/ prior anti-PD-1 tx</p><hr><a href=#toxicity><h2 id=toxicity><span class=hanchor arialabel=Anchor># </span>Toxicity</h2></a></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>â†©ï¸ åå‘é€£çµ</h3><ul class=backlinks><li>ğŸ¤­æ²’æœ‰æ‰¾åˆ°åå‘é€£çµ</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>ğŸ¤¯äº’å‹•åœ–</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>æœ¬ç¶²ç«™æ˜¯ç”± Hsieh-Ting Lin ä»¥â¤ï¸ ç”¨ <a href=https://github.com/jackyzha0/quartz>Quartz</a>é€™å€‹é…·æ±è¥¿ç¨®å‡ºä¾†ğŸª´ , Â© 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>ğŸ é¦–é </a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>